by rvvadmin | Sep 28, 2022 | 2022
TORONTO, Sept. 28, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...
by rvvadmin | Sep 16, 2022 | 2022
TORONTO, Sept. 16, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...
by rvvadmin | Sep 14, 2022 | 2022
TORONTO, Sept. 14, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...
by rvvadmin | Aug 19, 2022 | 2022
Notice of Annual and Special Meeting Of Shareholders Notice of Meeting and Management Information Circular for the Annual And Special Meeting of Shareholders to be held on September 19, 2022 Form of Proxy Voting Instruction Form Request for Financial Statements Email...
by rvvadmin | Aug 16, 2022 | 2022
TORONTO, Aug. 16, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
